http://www.fpnotebook.com/
NaloxoneAka: Narcan, Very Low Dose Naloxone Protocol
- See Also
- Physiology
- Pure Narcotic antagonist
- Action in under 2 minutes
- Effect lasts 45 minutes
- Indication: Narcotic overdosage
- Respiratory depression
- Sedation
- Hypotension
- Hypoperfusion
- Narcotic examples reversed by naloxone
- Heroin
- Methadone
- Pentazocine
- Propoxyphene
- Narcotics requiring increased naloxone dosing
- Propoxyphene
- Pentazocine
- Buprenorphine
- Pharmacokinetics
- Onset: 1-2 minutes
- Duration: 1-2 hours
- Dosing: General
- Route:
- Reliable: IV, IO, and ET
- Erratic absorption: IM and SQ
- Single dose
- Child
- Under 5 years (under 20 kilograms): 0.1 mg/kg
- Over 5 years (over 20 kilograms): 2.0 mg
- Adult
- Dose: 0.4 to 2.0 mg IVP
- Start with 0.4 mg if suspecting severe withdrawal
- Child
- Repeat dosing
- May repeat at 2-3 minutes intervals
- Maximum total dose: 10 mg
- Infusion (for long acting Narcotic reversal)
- Dose: 0.04 to 0.16 mg/kg/h
- Route:
- Dosing: Very Low Dose Naloxone Protocol
- Indications: Prevent severe rebound pain that would occur with complete Opioid reversal
- Prepare a 0.04 mg/ml Naloxone solution
- Start with one naloxone ampule 0.04 mg/ml
- Add saline to make total dose of 10 ml
- Dosing protocol
- Administer 0.01 to 0.04 mg (or 1.5 mcg/kg) IV or IM
- Repeat dose every 3-5 minutes as needed
- Titrate dose to Respiratory Rate and mental status
- Precautions
Naloxone (C0027358) | |
|---|---|
| Definition (MSH) | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Definition (CSP) | specific opiate antagonist with no agonist activity, a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Definition (NCI) | A thebaine derivate with competitive opioid antagonistic properties. Naloxone reverses the effects of opioid analgesics by binding to the opioid receptors in the CNS, and inhibiting the typical actions of opioid analgesics, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence. Naloxone binds to mu-opioid receptors with a high affinity, and a lesser degree to kappa- and gamma-opioid receptors in the CNS. |
| Definition (NCI) | A substance that is being studied as a treatment for constipation caused by narcotic medications. It belongs to the family of drugs called narcotic antagonists. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D009270 |
| English | Naloxone, NALOXONE PREPARATION, NLX |
| Spanish | naloxona |
| Parent Concepts | thebaine and derivatives (C0682977), Morphine (C0026549), Narcotic Antagonists (C0027410), Morphinans (C0026548), [CN102] OPIOID ANTAGONIST ANALGESICS (C0973498), Drug allergen (C1320237), Drugs used to treat addiction (C1629845) |
| Sources | AOD, CSP, LCH, LNC, MSH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Narcan (C0684237) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D009270 |
| English | Boots Brand of Naloxone Hydrochloride, Bristol Myers Squibb Brand of Naloxone Hydrochloride, Bristol-Myers Squibb Brand of Naloxone Hydrochloride, Endo Brand of Naloxone Hydrochloride, Lamepro Brand of Naloxone Hydrochloride, Narcan, Narcanti, United Drug Brand of Naloxone Hydrochloride |
| Sources | AOD, MSH, MTH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
